Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer

Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer

<p>Abstract</p> <p>Background</p> <p>Stable disease (SD) has ambiguous clinical significance for patients according to the dominant Response Evaluation Criteria in Solid Tumours (RECIST). The primary aims of the study were: (1) to clarify the clinical significance of SD...

Full description

Bibliographic Details
Main Authors:	Li Songbai, Zhang Jingdong, Hu Xuejun, Yu Ping, Zhao Mingfang, Jin Bo, Teng Yuee, He Lijie, Gao Yaling, Liu Yunpeng
Format:	Article
Language:	English
Published:	BMC 2010-12-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/10/681

Similar Items

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
by: James L Gulley, et al.
Published: (2022-02-01)

RECIST and beyond
by: E Coche
Published: (2013-05-01)

INVITATION TO PARTICIPATE IN SYMPOSIUM ON RECIST AND BEYOND
by: MPRC, Pusat Media & Perhubungan Awam
Published: (2016)

Determination of the surface recistivity of a textile fabric
by: 8096 British Standards Institution
Published: (1984)

RECIST 1.1 CRITERIA IN THE ASSESSMENT OF LUNG TUMORS
by: O. N. Chernova, et al.
Published: (2017-03-01)

Chemotherapeutic Resistance: Surviving Stressful Situations
by: Gilbert, Luke Andrew, et al.
Published: (2012)

m-RECIST at 1 month and Child A are survival predictors after percutaneous ethanol injection of hepatocellular carcinoma
by: Mauricio F. Silva, et al.
Published: (2014-11-01)

Multilingual RECIST classification of radiology reports using supervised learning
by: Luc Mottin, et al.
Published: (2023-06-01)

Imaging endpoints for clinical trial use: a RECIST perspective
by: Saskia Litiere, et al.
Published: (2022-11-01)

iRECIST and atypical patterns of response to immuno-oncology drugs
by: Emiliano Calvo, et al.
Published: (2022-06-01)

How Using Dedicated Software Can Improve RECIST Readings
by: Amandine René, et al.
Published: (2014-09-01)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
by: Flora Mulkey, et al.
Published: (2020-05-01)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
by: Jae Seung Lee, et al.
Published: (2020-11-01)

Tumor therapeutics in the era of “RECIST”: past, current insights, and future prospects
by: Zhilong Xu, et al.
Published: (2024-10-01)

RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis
by: Yao Yang, et al.
Published: (2022-06-01)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
by: Christelle de La Fouchardière, et al.
Published: (2020-10-01)

Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations
by: Kai Xiong, et al.
Published: (2024-07-01)

Survival after initial lung metastasectomy for metastatic colorectal cancer in the modern chemotherapeutic era
by: Shintaro Yokoyama, et al.
Published: (2017-05-01)

Automatic segmentation of hepatic metastases on DWI images based on a deep learning method: assessment of tumor treatment response according to the RECIST 1.1 criteria
by: Xiang Liu, et al.
Published: (2022-12-01)

Assessing immunotherapy response: going beyond RECIST by integrating early tumor growth kinetics
by: Mehdi Felfli, et al.
Published: (2024-12-01)

Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?
by: Valentina Magri, et al.
Published: (2024-02-01)

Accurate and Reproducible Application of the RECIST Criteria in CT Reporting in Oncology: A Learning Module
by: Nancy McNulty, et al.
Published: (2010-06-01)

Are modified RECIST the gold standard for response assessment of lung tumours treated with microwave ablation?
by: Masaki Bannai, et al.
Published: (2019-01-01)

Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.
by: Natalie M Lowe, et al.
Published: (2018-01-01)

RECIST 1.1 assessments variability: a systematic pictorial review of blinded double reads
by: Antoine Iannessi, et al.
Published: (2024-08-01)

Reproducing RECIST lesion selection via machine learning: Insights into intra and inter-radiologist variation
by: Teresa M. Tareco Bucho, et al.
Published: (2024-06-01)

Transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma: response analysis with mRECIST
by: Claudia Domaratius, et al.
Published: (2021-01-01)

mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization
by: Hippocrates Moschouris, et al.
Published: (2014-03-01)

Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?
by: Hubert Beaumont, et al.
Published: (2023-10-01)

Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma
by: Min Yin, et al.
Published: (2023-06-01)

A call for objectivity: Radiologists’ proposed wishlist for response evaluation in solid tumors (RECIST 1.1)
by: Kathleen Ruchalski, et al.
Published: (2024-11-01)

Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
by: Mary Kathryn Abel, et al.
Published: (2021-10-01)

Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT?
by: Panpan Yang, et al.
Published: (2023-01-01)

Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT
by: Kevin Zwirtz, et al.
Published: (2022-06-01)

Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer
by: Karen-Lise Garm Spindler, et al.
Published: (2023-04-01)

Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment
by: Marie Winter, et al.
Published: (2021-06-01)

Antibacterial chemotherapeutic agents /
by: 396429 Dax, Scott L.
Published: (1997)

Deitiforine, an Antiinfluenza Chemotherapeutic
by: S. N. Tandura, et al.
Published: (2020-05-01)

Chemotherapeutic of Niclofolan in the Treatment
by: T.J Fernandes, JR
Published: (2017-11-01)

The Prognostic Value of Total Tumor Volume Response Compared With RECIST1.1 in Patients With Initially Unresectable Colorectal Liver Metastases Undergoing Systemic Treatment
by: Nina J. Wesdorp, MD, et al.
Published: (2021-12-01)